MedTrace Logo

Evaluation of "Dose-dense Therapy" by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML)

NCT01382147 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 396

Last updated 2017-12-06

No results posted yet for this study

Summary

Evaluation weather early chemotherapy attempts for remission induction can improve the results of patients with Acute Myeloid Leukemia (AML), as compared to the standard group.

Conditions

Interventions

DRUG

Ara-C, Mitoxantrone, Daunorubicin, Thioguanin

Chemotherapy

Sponsors & Collaborators

  • Kompetenznetz Leukämien

    collaborator UNKNOWN

  • Prof. Dr. Wolfgang Hiddemann

    lead OTHER

Principal Investigators

  • Wolfgang Hiddemann, Prof. Dr. · Hospital of the University of Munich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-01
Primary Completion
2012-08-31
Completion
2017-07-05

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01382147 on ClinicalTrials.gov